Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba

Motaher Hossain, Kamrul Islam, Meagan Kelly, Leslie M.Mayo Smith, Richelle C. Charles, Ana A. Weil, Taufiqur Rahman Bhuiyan, Pavol Kováč, Peng Xu, Stephen B. Calderwood, Jakub K. Simon, Wilbur H. Chen, Michael Lock, Caroline E. Lyon, Beth D. Kirkpatrick, Mitchell Cohen, Myron M. Levine, Marc Gurwith, Daniel T. Leung, Andrew S. AzmanJason B. Harris, Firdausi Qadri, Edward T. Ryan

Research output: Contribution to journalArticlepeer-review

Abstract

Background Antibodies targeting O-specific polysaccharide (OSP) of Vibrio cholerae may protect against cholera; however, little is known about this immune response in infected immunologically naïve humans. Methodology We measured serum anti-OSP antibodies in adult North American volunteers experimentally infected with V. cholerae O1 Inaba El Tor N16961. We also measured vibriocidal and anti-cholera toxin B subunit (CtxB) antibodies and compared responses to those in matched cholera patients in Dhaka, Bangladesh, an area endemic for cholera. Principal findings We found prominent anti-OSP antibody responses following initial cholera infection: these responses were largely IgM and IgA, and highest to infecting serotype with significant crossserotype reactivity. The anti-OSP responses peaked 10 days after infection and remained elevated over baseline for . 6 months, correlated with vibriocidal responses, and may have been blunted in blood group O individuals (IgA anti-OSP). We found significant differences in immune responses between naïve and endemic zone cohorts, presumably reflecting previous exposure in the latter. Conclusions Our results define immune responses to O-specific polysaccharide in immunologically naive humans with cholera, find that they are largely IgM and IgA, may be blunted in blood group O individuals, and differ in a number of significant ways from responses in previously humans. These differences may explain in part varying degrees of protective efficacy afforded by cholera vaccination between these two populations. Trial registration number ClinicalTrials.gov NCT01895855.

Original languageEnglish (US)
Article numbere0007874
JournalPLoS neglected tropical diseases
Volume13
Issue number11
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba'. Together they form a unique fingerprint.

Cite this